Characterization of a novel POLD1 missense founder mutation in a Spanish population


Por: Ferrer-Avargues R, Diez-Obrero V, Martin-Tomas E, Hernandez-Illan E, Castillejo M, Codoner-Alejos A, Barbera V, Sanchez-Heras A, Segura A, Juan M, Tena I, Castillejo A, Soto J

Publicada: 1 abr 2017
Resumen:
Background: We identified a new and a recurrent POLD1 mutation associated with predisposition to colorectal cancer (CRC). We characterized the molecular and clinical nature of the potential POLD1 founder mutation in families from Valencia (Spain). Methods: Clinical and molecular data were collected from four independent families known to have a POLD1 Leu474Pro mutation. To establish its founder effect, haplotype construction was performed using 14 flanking POLD1 polymorphic markers. We calculated penetrance estimates and clinical expressivity, globally and stratified by age and sex. Results: We included 32 individuals from the four families: 20 carriers and 12 noncarriers. A common haplotype was identified in these families in a region comprising 2,995 Mb, confirming L474P as the first founder POLD1 mutation identified. Thirteen tumors diagnosed in 10 POLD1 carriers: eight CRC, three endometrial and two other tumors were considered. The median age of cancer onset for POLD1 mutation carriers was 48 years. The observed penetrance was 50% and the cumulative risk at age of 50 years was 30%. Conclusions: The findings of the present study contribute to a better understanding of CRC genetics in the Spanish population. The clinical phenotype for this mutation is similar to that in Lynch syndrome. Future studies using next generation sequencing with large gene panels for any hereditary cancer condition will offer the possibility of detecting POLE/POLD1 mutations in unsuspected clinical situations, demonstrating a more real and unbiased picture of the associated phenotype.

Filiaciones:
Ferrer-Avargues R:
 Hosp Univ Elche, Unidad Genet Mol, Elche, Spain

Diez-Obrero V:
 Hosp Univ Elche, Unidad Genet Mol, Elche, Spain

Martin-Tomas E:
 Hosp Univ Elche, Anal Clin, Elche, Spain

Hernandez-Illan E:
 Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante, Spain

 Hosp Univ Alicante, Unidad Invest, Alicante, Spain

Castillejo M:
 Hosp Univ Elche, Unidad Genet Mol, Elche, Spain

Codoner-Alejos A:
 Hosp Univ Elche, Unidad Genet Mol, Elche, Spain

Barbera V:
 Hosp Univ Elche, Unidad Genet Mol, Elche, Spain

 Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante, Spain

Sanchez-Heras A:
 Hosp Univ Elche, Consejo Genet Canc, Elche, Spain

Segura A:
 Hosp Univ La Fe, Consejo Genet Canc, Valencia, Spain

Juan M:
 Fdn Inst Valenciano Oncol, Consejo Genet Canc, Valencia, Spain

Tena I:
 Hosp Prov Castellon, Consejo Genet Canc, Castellon de La Plana, Spain

Castillejo A:
 Hosp Univ Elche, Unidad Genet Mol, Elche, Spain

Soto J:
 Hosp Univ Elche, Unidad Genet Mol, Elche, Spain

 Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante, Spain
ISSN: 1099498X





Journal Of Gene Medicine
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 19 Número: 4
Páginas:
WOS Id: 000403097300004
ID de PubMed: 28306219

MÉTRICAS